Thermo Fisher Scientific Completes Sale of Genevac

Apr 04, 2007

NEW YORK (GenomeWeb News) — Thermo Fisher Scientific today said it has completed the sale of its Genevac business to Riverlake Equity Partners.

Thermo said Genevac brought in around $17 million in annual sales.

Registering provides access to this and other free content.

Already have an account?
Login Now.

Breaking News

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

In Nature this week: a Danish reference genome, and more.